Upadacitinib was found to have achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity at week 14.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.